Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Perspective Therapeutics Inc (CATX)

Perspective Therapeutics Inc (CATX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 417,018
  • Shares Outstanding, K 67,588
  • Annual Sales, $ 1,430 K
  • Annual Income, $ -46,510 K
  • EBIT $ -59 M
  • EBITDA $ -58 M
  • 60-Month Beta 1.46
  • Price/Sales 319.56
  • Price/Cash Flow N/A
  • Price/Book 1.39

Options Overview Details

View History
  • Implied Volatility 140.54% ( +21.27%)
  • Historical Volatility 104.18%
  • IV Percentile 59%
  • IV Rank 55.85%
  • IV High 247.48% on 10/09/24
  • IV Low 5.25% on 08/13/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 46
  • Volume Avg (30-Day) 42
  • Put/Call OI Ratio 1.89
  • Today's Open Interest 1,841
  • Open Int (30-Day) 1,925

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.25
  • Number of Estimates 5
  • High Estimate -0.19
  • Low Estimate -0.29
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.60 unch
on 11/21/24
12.90 -64.34%
on 11/04/24
-8.10 (-63.78%)
since 10/21/24
3-Month
4.60 unch
on 11/21/24
16.55 -72.21%
on 08/26/24
-10.72 (-69.97%)
since 08/21/24
52-Week
2.28 +101.75%
on 12/13/23
19.05 -75.85%
on 05/15/24
+2.02 (+78.16%)
since 11/21/23

Most Recent Stories

More News
Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

CATX : 4.67 (-24.28%)
Perspective Therapeutics, Inc. to Present Initial Results of [212Pb]VMT-α-NET Phase 1/2a Trial at NANETS Symposium

Perspective Therapeutics will present Phase 1/2a trial results for [212Pb]VMT-α-NET at the NANETS symposium on November 22, 2024.Quiver AI SummaryPerspective Therapeutics, Inc. announced details of an...

CATX : 4.67 (-24.28%)
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

CATX : 4.67 (-24.28%)
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

CATX : 4.67 (-24.28%)
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results

CATX : 4.67 (-24.28%)
Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

CATX : 4.67 (-24.28%)
Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

CATX : 4.67 (-24.28%)
Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

CATX : 4.67 (-24.28%)
Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

CATX : 4.67 (-24.28%)
Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research

CATX : 4.67 (-24.28%)

Business Summary

Perspective Therapeutics Inc. is a medical technology and radiopharmaceutical company which provide advanced treatment applications for cancers. The Company is the sole producer of Cesium-131 brachytherapy seeds. Perspective Therapeutics Inc., formerly known as Isoray Inc., is based in RICHLAND, Wash....

See More

Key Turning Points

3rd Resistance Point 7.54
2nd Resistance Point 7.20
1st Resistance Point 6.69
Last Price 4.67
1st Support Level 5.83
2nd Support Level 5.49
3rd Support Level 4.98

See More

52-Week High 19.05
Fibonacci 61.8% 12.64
Fibonacci 50% 10.66
Fibonacci 38.2% 8.69
Last Price 4.67
52-Week Low 2.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar